PubRank

Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma (PANORAMA-1)

Clinical Trial ID NCT01023308

PubWeight™ 25.20‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01023308

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov 2012 6.70
2 Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014 3.62
3 Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol 2012 2.25
4 Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013 1.04
5 Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 2015 0.94
6 The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol 2011 0.94
7 The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol 2014 0.88
8 Targeting Histone Deacetylases in Diseases: Where Are We? Antioxid Redox Signal 2014 0.88
9 Epigenetic Therapeutics: A New Weapon in the War Against Cancer. Annu Rev Med 2016 0.87
10 Genomic and Epigenomic Alterations in Cancer. Am J Pathol 2016 0.86
11 Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol 2016 0.79
12 Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma. Sci Rep 2015 0.78
13 Immunotherapeutic approaches to treat multiple myeloma. Hum Vaccin Immunother 2013 0.77
14 Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Eur J Clin Pharmacol 2015 0.76
15 Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther 2016 0.76
16 Experimental approaches in the treatment of multiple myeloma. Ther Adv Hematol 2011 0.76
17 Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clin Epigenetics 2010 0.76
18 The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther 2016 0.75
19 Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor. Onco Targets Ther 2016 0.75
Next 100